Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...

The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...

FDA approves 1st biosimilar to Perjeta, Poherdy, for HER2-positive breast cancer treatment, enabling pharmacy-level substitution under state law.

So, I think more to come on how first line selection might evolve in the next few years depending on results from other ...

The agreement with EirGenix grants Sandoz exclusive rights to commercialize proposed biosimilar of pertuzumab for treatment ...

As Roche works to switch certain patients with breast cancer over to a fixed-dose combination of two medicines, its ...

Pertuzumab-dpzb is now considered an interchangeable biosimilar to pertuzumab as part of treatment combinations in multiple ...